/IBT-B.ST
IBT-B.ST Stock - Infant Bacterial Therapeutics AB (publ)
Healthcare|BiotechnologySTO
$49.00+2.73%
+$1.30 (+2.73%) • Dec 23
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $53.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IBT-B.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$48.51 – $49.49
TARGET (TP)$56.35
STOP LOSS$45.08
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.24
52W High$84.30
52W Low$31.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4,000 | $77,000 | $12,000 | N/A | N/A |
| Gross Profit | $4,000 | $77,000 | $12,000 | N/A | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-139,902,000 | $-134,617,000 | $-65,808,000 | $-44,578,000 | $-71,918,000 |
| Net Income | $-136,905,000 | $-123,068,000 | $-65,451,000 | $-44,991,000 | $-72,310,000 |
| Net Margin | -3422625.0% | -159828.6% | -545425.0% | N/A | N/A |
| EPS | $-10.16 | $-9.95 | $-5.83 | $-4.01 | $-6.44 |
Company Overview
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IBT-B.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.75
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 6, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.75 | — | — |
Q3 2025 | Aug 20, 2025 | — | $-1.42 | — | — |
Q2 2025 | May 7, 2025 | — | $-1.24 | — | — |
Q1 2025 | Feb 13, 2025 | — | $-2.51 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-2.42 | — | — |
Q3 2024 | Aug 28, 2024 | — | $-3.17 | — | — |
Q2 2024 | May 7, 2024 | — | $-2.06 | — | — |
Q1 2024 | Feb 8, 2024 | — | $-3.04 | — | — |
Q4 2023 | Nov 10, 2023 | — | $-2.31 | — | — |
Q3 2023 | Aug 25, 2023 | — | $-2.57 | — | — |
Q2 2023 | May 8, 2023 | — | $-2.00 | — | — |
Q1 2023 | Feb 10, 2023 | — | $-3.52 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.70 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.15 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-1.72 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.44 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-2.60 | — | — |
Latest News
Loading news...
Frequently Asked Questions about IBT-B.ST
What is IBT-B.ST's current stock price?
Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is currently trading at $49.00 per share. The stock has moved +2.73% today.
What is the analyst price target for IBT-B.ST?
No analyst price targets are currently available for this stock.
What sector is Infant Bacterial Therapeutics AB (publ) in?
Infant Bacterial Therapeutics AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is IBT-B.ST's market cap?
Infant Bacterial Therapeutics AB (publ) has a market capitalization of $0.64 billion, making it a small-cap company.
Does IBT-B.ST pay dividends?
No, Infant Bacterial Therapeutics AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADDV-B.ST
ADDvise Group AB (publ)
$1.62
Mkt Cap: $1.0B
CANTA.ST
Cantargia AB (publ)
$4.09
Mkt Cap: $1.0B
CLBIO.ST
Corline Biomedical AB
$16.35
Mkt Cap: $0.4B
GUARD.ST
Guard Therapeutics International AB (publ)
$1.40
Mkt Cap: $0.0B
ITECH.ST
I-Tech AB
$52.80
Mkt Cap: $0.6B
ONCO.ST
Oncopeptides AB (publ)
$4.57
Mkt Cap: $1.0B
SEZI.ST
Senzime AB (publ)
$5.26
Mkt Cap: $0.8B
SYNACT.ST
SynAct Pharma AB
$23.80
Mkt Cap: $1.3B
XINT.ST
Xintela AB (publ)
$0.27
Mkt Cap: $0.2B
XSPRAY.ST
Xspray Pharma AB (publ)
$31.20
Mkt Cap: $1.1B
Explore stocks similar to IBT-B.ST for comparison